Yayınlar & Eserler

Yayın Ağı
Makaleler 25
Tümü (25)
SCI-E, SSCI, AHCI (20)
SCI-E, SSCI, AHCI, ESCI (22)
ESCI (2)
Scopus (24)
TRDizin (5)

1. Prognostic Value of Baseline Sarcopenia and Adipose Tissue Indices in HR+/HER2− Metastatic Breast Cancer Treated with CDK4/6 Inhibitors: A Retrospective Cohort Study

Karahan L., Akyildiz A., Sahin T. K., Batu M. A., ERŞAN Y. Ç., ONUR M. R., et al.
Journal of Clinical Medicine , cilt.15, sa.4, 2026 (SCI-Expanded, Scopus) identifier identifier

2. Efficacy, Safety, and Survival Outcomes of Immune Checkpoint Inhibitors in Patients with Mismatch Repair-Deficient Colorectal Cancer: A Retrospective, Multicenter Study

İcli M. C., GÜVEN D. C., Akyildiz A., Gürbüz A. F., Majidova N., Kıdı M. M., et al.
Journal of Clinical Medicine , cilt.15, sa.4, 2026 (SCI-Expanded, Scopus) identifier identifier

3. Efficacy of Second-Line Treatments After Atezolizumab and Bevacizumab in Advanced Hepatocellular Carcinoma and Related Prognostic Factors: A Multicenter Study by the Turkish Oncology Group (TOG)

Majidova N., YASLIKAYA Ş., Mildanoglu M. M., COŞKUN A., ERCAN UZUNDAL D., ŞAHİN T. K., et al.
TURKISH JOURNAL OF GASTROENTEROLOGY , cilt.36, sa.5, ss.293-301, 2025 (SCI-Expanded, Scopus, TRDizin) identifier identifier identifier

4. Bi-weekly irinotecan is an effective and convenient regimen in the treatment of relapsed or refractory small cell lung cancer

YILMAZ F., YAŞAR S., Tatar O. D., Yildirim H. C., Guven D. C., AKYILDIZ A., et al.
BMC CANCER , cilt.24, sa.1, 2024 (SCI-Expanded, Scopus) identifier identifier identifier

5. Sorafenib vs chemotherapy in the treatment of locally advanced or metastatic, radioactive iodine-refractory differentiated thyroid cancer: real-world data from Turkey

Majidova N., Aghamaliyeva S., Guliyev M., Dinc G., AKYILDIZ A., Ozcan E., et al.
JOURNAL OF CHEMOTHERAPY , 2024 (SCI-Expanded, Scopus) identifier identifier identifier

6. Impact of trastuzumab emtansine (T-DM1) on spleen volume in patients with HER2-positive metastatic breast cancer

AKYILDIZ A., Ismayilov R., Abdurrahimli N., Ormanci A., GÜVEN D. C., TUNCEL M., et al.
JAPANESE JOURNAL OF CLINICAL ONCOLOGY , sa.2, ss.100-105, 2024 (SCI-Expanded, Scopus) identifier identifier

7. Efficacy of cumulative cisplatin dose on survival in patients with locally advanced cervical cancer treated with definitive chemoradiotherapy: multicenter study by Turkish Oncology Group

AKYILDIZ A., GÜLTEKİN M., YİĞİT E., Demir E., Ismayilov R., AHMED M. A., et al.
INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER , cilt.34, ss.1359-1365, 2024 (SCI-Expanded, Scopus) Sürdürülebilir Kalkınma identifier identifier identifier

8. Real-world evaluation of nivolumab in patients with non-nasopharyngeal recurrent or metastatic head and neck cancer: a retrospective multi-center study by the Turkish Oncology Group (TOG)

AKYILDIZ A., GÜVEN D. C., KÖKSAL B., KARAOĞLAN B. B., Kivrak D., Ismayilov R., et al.
EUROPEAN ARCHIVES OF OTO-RHINO-LARYNGOLOGY , cilt.281, sa.9, ss.4991-4999, 2024 (SCI-Expanded, Scopus) Creative Commons License Sürdürülebilir Kalkınma identifier identifier identifier

9. Erken Evre Serviks Kanseri Hastalarında Progresyonun Öngördürücüsü Olarak Nötrofil Lenfosit Oranı

Akyıldız A., Ismayilov R., Arık Z.
Journal of medicine and palliative care (Online) , cilt.5, sa.4, ss.203-207, 2024 (TRDizin) Creative Commons License identifier

10. Effect of hypoxia-inducible factor-1 alpha expression on survival in patients with metastatic cervical squamous cell carcinoma treated with first-line chemotherapy and bevacizumab

YILDIRIM H. Ç., Anik H., ATEŞ ÖZDEMİR D., Ismayilov R., AKYILDIZ A., ÇAYIRÖZ K., et al.
BIOMOLECULES AND BIOMEDICINE , cilt.24, sa.4, ss.998-1003, 2024 (SCI-Expanded, Scopus) identifier identifier identifier

11. Prognostic Significance of Pan-Immune-Inflammation Value in Patients with HER2-Positive Metastatic Breast Cancer Treated with Trastuzumab Emtansine

ŞAHİN T. K., AKYILDIZ A., DOĞAN O. T., KAVGACI G., GÜVEN D. C., AKSOY S.
PHARMACEUTICALS , cilt.17, sa.7, 2024 (SCI-Expanded, Scopus) Creative Commons License identifier identifier identifier

12. Comprehensive analysis of orbital lymphoma in a Turkish cohort: clinical characteristics, histological subtypes, treatment modalities, prognostic factors, and implications for management

AKYILDIZ A., Ismayilov R., Rustamova N., Tokatli M., KOÇ İ., AKIN S., et al.
Annals of Hematology , cilt.103, sa.3, ss.905-915, 2024 (SCI-Expanded, Scopus) identifier identifier identifier

13. Sirolimus experience in adult patients with vascular malformations

AKYILDIZ A., Ismayilov R., GÜVEN D. C., YILDIRIM H. Ç., Tatar O. D., KUŞ F., et al.
Vascular , 2024 (SCI-Expanded, Scopus) identifier identifier identifier

14. The Use of Herbal Medicine and Dietary Supplements in Cancer Patients Receiving Immune Checkpoint Inhibitors: A Multicenter Cross-Sectional Study

KUŞ F., GÜVEN D. C., YILDIRIM H. Ç., Akagunduz B., Karakaya S., SÜTCÜOĞLU O., et al.
INTEGRATIVE CANCER THERAPIES , cilt.23, 2024 (SCI-Expanded, Scopus) identifier identifier identifier

15. A meta-analysis of the association between adjuvant chemoradiotherapy and disease-free survival in gastric cancer according to the histology

YILDIRIM H. Ç., GÜVEN D. C., AKYILDIZ A., YALÇIN Ş., DİZDAR Ö.
Irish Journal of Medical Science , cilt.192, sa.6, ss.2631-2634, 2023 (SCI-Expanded, Scopus) Sürdürülebilir Kalkınma identifier identifier identifier

16. The safety and efficacy of first-line atezolizumab plus bevacizumab in patients with unresectable hepatocellular carcinoma: A multicenter real-world study from Turkey

AKYILDIZ A., GÜVEN D. C., Ozluk A. A., Ismayilov R., Mutlu E., Unal O. U., et al.
Medicine , cilt.102, sa.45, 2023 (SCI-Expanded, Scopus) identifier identifier identifier

17. A chance in hopeless cancer: 5-year complete remission after oxaliplatin-based therapy in a patient with BRCA2 mutant metastatic pancreatic cancer

YILDIRIM H. Ç., Ismayilov R., AKYILDIZ A., GÜVEN D. C., Abdurrahimli N., DİZDAR Ö., et al.
Anti-cancer drugs , cilt.34, sa.10, ss.1190-1192, 2023 (SCI-Expanded, Scopus) identifier identifier identifier

18. Efficacy of Capecitabine and Temozolomide Regimen in Neuroendocrine Tumors: Data From the Turkish Oncology Group

Ünal Ç., AZİZY A., KARABULUT S., TAŞTEKİN D., AKYILDIZ A., YAŞAR S., et al.
The oncologist , cilt.28, sa.10, ss.875-884, 2023 (SCI-Expanded, Scopus) Creative Commons License identifier identifier identifier

19. Do statins enhance the antitumor effect of trastuzumab emtansine (T-DM1)?: Real-life cohort

AKYILDIZ A., GÜVEN D. C., YILDIRIM H. Ç., Ismayilov R., YILMAZ F., Tatar O. D., et al.
Medicine (United States) , cilt.102, sa.18, 2023 (SCI-Expanded, Scopus) identifier identifier identifier

20. KELIM score predicts outcome in patients with platinum-resistant/refractory recurrent ovarian cancer

KUŞ F., Guven D. C., YILDIRIM H. Ç., Chalabiyev E., AKYILDIZ A., Tatar O. D., et al.
Biomarkers in Medicine , cilt.17, sa.7, ss.379-389, 2023 (SCI-Expanded, Scopus) identifier identifier identifier

21. Prognostic Value of Androgen Receptor Expression in Premenopausal Women with Estrogen Receptor-Positive Breast Cancer

YILDIRIM H. Ç., ÜNER M., Yildiran Özmen T., Chalabiyev E., GÜVEN D. C., KUŞ F., et al.
Journal of Oncological Science , cilt.9, sa.1, ss.33-37, 2023 (Scopus, TRDizin) Creative Commons License identifier identifier

22. Assessing the Clinical Impact of Lutetium-177 DOTATATE Peptide Receptor Radionuclide Therapy (PRRT) on Metastatic Neuroendocrine Tumors: A Multicenter Real-World Data from Türkiye

Unal C., Selcuk N. A., Biricik F. S., Alan O., Ordu C., Selvi O., et al.
Eurasian Journal of Medicine and Oncology , cilt.7, sa.3, ss.232-242, 2023 (ESCI, Scopus, TRDizin) Creative Commons License identifier identifier identifier

23. Emerging treatment strategies in hepatobiliary cancer

GÜVEN D. C., YILDIRIM H. Ç., Chalabiyev E., KUŞ F., YILMAZ F., YAŞAR S., et al.
Expert Review of Anticancer Therapy , cilt.23, sa.3, ss.243-256, 2023 (SCI-Expanded, Scopus) Sürdürülebilir Kalkınma identifier identifier identifier

24. Bilateral primary breast lymphoma in a pregnant woman: a case report and literature review

YILDIRIM H. Ç., AKYILDIZ A., Ismayilov R., Demirok N., BENLİ B. S., Guven D. C., et al.
MEMO-MAGAZINE OF EUROPEAN MEDICAL ONCOLOGY , cilt.15, sa.4, ss.307-310, 2022 (ESCI, Scopus) identifier identifier

25. Prognostic Factors Associated with Locally Advanced Gastric Cancer in Patients Treated with Adjuvant Chemotherapy

YILDIRIM H. Ç., Güven D. C., Chalabiyev E., Taban H., YILMAZ F., YAŞAR S., et al.
Journal of Oncological Science , cilt.8, sa.3, ss.143-147, 2022 (Scopus, TRDizin) Creative Commons License Sürdürülebilir Kalkınma identifier identifier
Hakemli Bilimsel Toplantılarda Yayımlanmış Bildiriler 2

1. The efficacy of cumulative cisplatin dose on survival in patients with locally advanced cervical cancer treated with definitive chemoradiotherapy: A multicenter study by the Turkish Oncology Group (TOG)

Akyildiz A., GÜLTEKİN M., Yigit E., Demir E., Ismayilov R., AHMED M. A., et al.
Special Clinical Science Symposia, ELECTR NETWORK, 29 Mayıs 2024, (Özet Bildiri) identifier

2. Real-world evaluation of nivolumab in patients with non-nasopharyngeal recurrent or metastatic head and neck cancer: A retrospective multi-center study by the Turkish Oncology Group (TOG).

Akyildiz A., Guven D. C., Koksal B., Karaoglan B. B., Salim D. K., Sutcuoglu O., et al.
Special Clinical Science Symposia, ELECTR NETWORK, 29 Mayıs 2024, (Özet Bildiri) identifier
Metrikler

Yayın

27

Yayın (WoS)

24

Yayın (Scopus)

24

Atıf (WoS)

1

H-İndeks (WoS)

1

Açık Erişim

7
BM Sürdürülebilir Kalkınma Amaçları